- Home
- GGR vs ENTX Comparison
GGR vs ENTX Comparison
Compare GGR & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGR
- ENTX
- Stock Information
- Founded
- GGR 2011
- ENTX 2010
- Country
- GGR Taiwan
- ENTX Israel
- Employees
- GGR N/A
- ENTX N/A
- Industry
- GGR Auto Manufacturing
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GGR Consumer Discretionary
- ENTX Health Care
- Exchange
- GGR Nasdaq
- ENTX Nasdaq
- Market Cap
- GGR 114.3M
- ENTX 104.0M
- IPO Year
- GGR N/A
- ENTX 2018
- Fundamental
- Price
- GGR $0.25
- ENTX $1.98
- Analyst Decision
- GGR Hold
- ENTX Strong Buy
- Analyst Count
- GGR 2
- ENTX 1
- Target Price
- GGR $0.50
- ENTX $10.00
- AVG Volume (30 Days)
- GGR 317.1K
- ENTX 42.8K
- Earning Date
- GGR 08-14-2025
- ENTX 08-08-2025
- Dividend Yield
- GGR N/A
- ENTX N/A
- EPS Growth
- GGR N/A
- ENTX N/A
- EPS
- GGR N/A
- ENTX N/A
- Revenue
- GGR $304,551,000.00
- ENTX $223,000.00
- Revenue This Year
- GGR N/A
- ENTX N/A
- Revenue Next Year
- GGR $5.00
- ENTX N/A
- P/E Ratio
- GGR N/A
- ENTX N/A
- Revenue Growth
- GGR N/A
- ENTX N/A
- 52 Week Low
- GGR $0.19
- ENTX $1.41
- 52 Week High
- GGR $1.76
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- GGR 42.72
- ENTX 48.00
- Support Level
- GGR $0.25
- ENTX $1.87
- Resistance Level
- GGR $0.27
- ENTX $2.18
- Average True Range (ATR)
- GGR 0.01
- ENTX 0.18
- MACD
- GGR 0.00
- ENTX -0.00
- Stochastic Oscillator
- GGR 11.15
- ENTX 31.82
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.